Puma Biotechnology, Inc.

What they do

Puma commercializes NERLYNX, an oral irreversible pan-HER tyrosine kinase inhibitor, for two FDA-approved indications: extended adjuvant treatment of early stage HER2-overexpressed/amplified breast cancer after adjuvant trastuzumab, and in combination with capecitabine for advanced or metastatic HER2-positive breast cancer after two or more prior anti-HER2 regimens. It sells NERLYNX in the U.S. through a direct specialty sales force of approximately 35 sales specialists as of December 31, 2025, and relies on exclusive third-party sub-licensees in more than 40 countries outside the U.S. The company also in-licensed alisertib, an Aurora Kinase A inhibitor previously tested in over 1,300 patients across 22 Takeda-sponsored trials, and is responsible for its global development and commercialization.

Revenue drivers

• NERLYNX U.S. product revenue — Net product revenue comes entirely from NERLYNX sales and was $53.6 million in Q2 2026 and $95.5 million in the first half of 2026; the U.S. business is served by a roughly 35-person direct specialty sales force.
• Royalty revenue from ex-U.S. sub-licensees — Royalties from third-party sub-licensees commercializing NERLYNX outside the U.S. contributed $2.9 million in Q2 2026 and $5.8 million in the first half of 2026, a small share of total revenue.
• Alisertib development programs — Alisertib is not approved or revenue-generating; the company is running the ALISCA-Breast1 and ALISCA-Lung1/Lung2 trials in HER2-negative hormone receptor-positive metastatic breast cancer and extensive stage small cell lung cancer.

Recent performance

Second quarter 2026 total revenue was $56.5 million, up from $52.4 million a year earlier, comprising $53.6 million of net product revenue and $2.9 million of royalty revenue. GAAP net income was $8.2 million, or $0.16 per basic and diluted share, versus $5.9 million, or $0.12 per share, in Q2 2025; first-half 2026 net income was $4.4 million versus $8.8 million. Research and development expense rose to $18.9 million in Q2 2026 from $15.5 million a year earlier, while SG&A declined to $17.5 million from $18.0 million. Net cash provided by operating activities was $1.6 million in Q2 2026 versus $14.1 million in Q2 2025, and $17.0 million for the first half of 2026 versus $17.7 million. On May 4, 2026, the company made the final payment under its 2021 Note Purchase Agreement, reducing outstanding debt to zero.

Strategy

Management said it is focused on continued commercial execution for NERLYNX in the second half of 2026 and on advancing alisertib through the ALISCA trials. Stated near-term milestones include initiating enrollment in ALISCA-Lung2, a Phase I/II trial of alisertib plus paclitaxel in extensive stage small cell lung cancer, in Q3 2026; expanding enrollment in ALISCA-Breast1 in chemotherapy-naive HER2-negative, hormone receptor-positive metastatic breast cancer in H2 2026; expanding ALISCA-Lung1 monotherapy enrollment in H2 2026; and presenting updated ALISCA-Breast1 data in Q4 2026. The company also raised 2026 revenue and net income guidance based on increased demand for NERLYNX. It has no long-term debt following the May 2026 payoff of its note purchase agreement.

Risks

• Single-product concentration — The company describes itself as a single product company; all product revenue comes from NERLYNX, and it depends on a limited number of customers for a significant amount of total revenue.
• Alisertib development risk — Alisertib is in early-stage development with all global development and commercialization responsibility assumed by Puma, and any failure to develop it would materially harm the business and financial position.
• Profitability not assured — Despite net income in 2023, 2024 and 2025, the company had an accumulated deficit of approximately $1,283.8 million as of December 31, 2025 and says it may incur operating losses in the future.
• Third-party dependence — Puma relies exclusively on third parties to formulate and manufacture NERLYNX and alisertib and on international sub-licensees to commercialize NERLYNX outside the U.S.

Outlook

Management raised 2026 revenue and net income guidance based on increased demand for NERLYNX and expects continued commercial execution in the second half of the year. It listed four expected milestones over the next 12 months, all tied to alisertib: ALISCA-Lung2 enrollment start in Q3 2026, ALISCA-Breast1 and ALISCA-Lung1 enrollment expansion in H2 2026, and updated ALISCA-Breast1 data in Q4 2026. The company reported $93.9 million in cash, cash equivalents and marketable securities at June 30, 2026, versus $97.5 million at December 31, 2025, and no outstanding debt.